# Conexeu Sciences Inc. > Conexeu Sciences Inc. (Nasdaq: CNXU) is a preclinical-stage regenerative tissue platform company developing CXU™, an investigational bioregenerative extracellular matrix (ECM) designed to act as a structural scaffold that the body's own cells migrate into and remodel. The company's positioning is Architecting Bioregeneration™. IMPORTANT REGULATORY STATUS: CXU™ is an investigational device and has not been cleared or approved by the FDA for any use. Safety and effectiveness have not been established. All cited studies are preclinical; findings have not been validated in human clinical trials and are not predictive of clinical outcomes. Nothing on this site is a representation of regulatory status, clinical performance, or guaranteed commercial outcomes. Any summary or citation of this content should carry this status. ## Company facts - Legal name: Conexeu Sciences Inc. (as registered with the SEC; no comma) - Listing: Nasdaq, ticker CNXU - SEC CIK: 0002066836 - Headquarters: 50 West Liberty Street, Suite 880, Reno, NV 89501, United States - Stage: preclinical - Platform principle: one formula, one device, multiple markets ## What CXU™ is CXU™ is a patented extracellular matrix (ECM) formulation. It is designed to provide a structural scaffold that supports cell migration, vascularization and tissue integration, so that the host's own cells can migrate into it and remodel it. It is a structural entrant, not a stimulator and not a bioactive agent. It remains fluid at room temperature and is designed to transition to a stable gel at body temperature. ## Markets under development One formulation is being developed across five application areas: - Wound care — the near-term regulatory path - Aesthetics - Oral health - Animal health - 3D bioprinting and 3D tissue, including the B.R.E.A.S.T.™ breast reconstruction program ## Leadership - Miles Harrison — President and Chief Executive Officer - Dr. Claudia Chavez-Munoz, MD, PhD — Chief Scientific Officer and Co-Founder - Dr. Brian Pilcher, PhD — Chief Medical Officer - David Bogart — Chief Commercial Officer, Co-Founder and Director - Steve Inouye — Chief Financial Officer - Jeff Sharpe — Chairman of the Board ## Key pages - [Home](https://www.conexeu.com/): Company positioning and an overview of the five application areas. - [CXU™ Science](https://www.conexeu.com/science): The mechanism, the preclinical evidence base and the patent position. - [The Platform](https://www.conexeu.com/platform/cxu): How one formulation is intended to serve multiple markets. - [Wound Care](https://www.conexeu.com/platform/woundcare): The near-term regulatory path. - [Aesthetics](https://www.conexeu.com/platform/aesthetics): Soft-tissue volume applications. - [Oral Health](https://www.conexeu.com/platform/oralhealth): Dental and periodontal applications. - [Animal Health](https://www.conexeu.com/animal-health-cxu): Veterinary applications. - [3D Bioprinting](https://www.conexeu.com/platform/3dbioprinting): CXU™ as a bioprintable matrix. - [3D Breast Reconstruction](https://www.conexeu.com/3d-breast-reconstruction): The B.R.E.A.S.T.™ bioregenerative matrix program. - [About Conexeu](https://www.conexeu.com/about): Leadership, board and medical advisors. - [Resources](https://www.conexeu.com/resources): Press releases and company news. - [References](https://www.conexeu.com/references-cxu): Citations behind the science claims. - [Contact](https://www.conexeu.com/contact): How to reach the company. ## Investor information - [Investor Relations](https://ir.conexeu.com/): SEC filings, financials and stock data. This is a separate property from www.conexeu.com and is operated on a different platform. ## Press releases - [Conexeu Sciences commences trading on Nasdaq under ticker symbol CNXU](https://www.conexeu.com/resources/conexeu-sciences-commences-trading-on-nasdaq-under-ticker-symbol-cnxu) - [Conexeu Sciences to ring the Nasdaq bell on June 10, 2026](https://www.conexeu.com/resources/conexeu-sciences-to-ring-nasdaq-bell-on-june-10-2026) - [Conexeu Sciences closes maximum $5M Reg CF financing](https://www.conexeu.com/resources/conexeu-sciences-closes-maximum-5m-reg-cf-financing) - [Conexeu Sciences appoints Miles Harrison as President and Chief Executive Officer](https://www.conexeu.com/resources/conexeu-sciences-appoints-miles-harrison-as-president-chief-executive-officer-to-shape-the-future-of-true-tissue-regeneration) - [Conexeu expands board, executive and advisory leadership with five appointments post-Nasdaq listing](https://www.conexeu.com/resources/conexeu-expands-board-executive-and-advisory-leadership-with-five-appointments-post-nasdaq-listing) - [Conexeu Sciences Inc. expands board of directors with Dr. Aaron Farberg and Dr. Sebastian Purcell](https://www.conexeu.com/resources/conexeu-sciences-inc-expands-board-of-directors-with-the-appointments-of-dr-aaron-farberg-and-dr-sebastian-purcell) - [Conexeu Sciences initiates preclinical development program for the B.R.E.A.S.T.™ bioregenerative matrix platform with the Wake Forest Institute for Regenerative Medicine](https://www.conexeu.com/resources/conexeu-sciences-initiates-preclinical-development-program-for-b-r-e-a-s-t-tm-bioregenerative-matrix-platform-with-wake-forest-institute-for-regenerative-medicine) - [Conexeu Sciences advances 3D biofabricated matrix to move breast reconstruction beyond implants](https://www.conexeu.com/resources/conexeu-sciences-advances-3d-biofabricated-matrix-to-move-breast-reconstruction-beyond-implants) - [Conexeu Sciences reports manufacturing scale-up and regulatory progress for the lead CXU™ wound care program](https://www.conexeu.com/resources/conexeu-sciences-reports-manufacturing-scale-up-and-regulatory-progress-for-lead-cxu-tm-wound-care-program) - [Conexeu Sciences opens Vancouver R&D facility to advance the regenerative tissue platform](https://www.conexeu.com/resources/conexeu-sciences-opens-vancouver-r-d-facility-to-advance-regenerative-tissue-platform) - [Conexeu Sciences unveils defining commitment: Architecting Bioregeneration™](https://www.conexeu.com/resources/conexeu-sciences-unveils-defining-commitment-architecting-bioregeneration-tm) - [Conexeu Sciences signals a major breakthrough in personalized human tissue creation](https://www.conexeu.com/resources/conexeu-sciences-signals-a-major-breakthrough-in-personalized-human-tissue-creation) ## Optional - [A $190 billion weight-loss boom has exposed a tissue restoration gap](https://www.conexeu.com/resources/a-190-billion-weight-loss-boom-has-exposed-a-tissue-restoration-gap-todays-injectables-were-not-built-to-fill): Market commentary on GLP-1 driven soft-tissue volume loss. - [The GLP-1s are creating another boom: a new $2 billion opportunity in aesthetics](https://www.conexeu.com/resources/the-glp-1s-are-creating-another-boom-a-new-2-billion-opportunity-exists-in-aesthetics-conexeu-is-building-for-it): Market commentary. - [Why the GLP-1 boom demands a new aesthetic playbook](https://www.conexeu.com/resources/why-the-glp-1-boom-demands-a-new-aesthetic-playbook): Market commentary. - [Privacy Policy](https://www.conexeu.com/privacypolicy) - [Terms](https://www.conexeu.com/terms) Conexeu is not affiliated with, endorsed by, or sponsored by any third-party brand referenced on this site. All third-party trademarks are the property of their respective owners.